Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus

Oncolytic virus therapy–foreword

Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions

p53-independent endoplasmic reticulum stress-mediated cytotoxicity of a Newcastle disease virus strain in tumor cell lines

Combined treatment of pediatric high-grade glioma with the oncolytic viral strain MTH-68/H and oral valproic acid

Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death

Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence

A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization

Combined action of virus injection and local tumor irradiation on tumor growth in mice

A tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes